Key Takeaways PODD reported Q4 EPS of $1.55, up 34.8%, as revenues rose 31.2% and beat estimates.Insulet's Omnipod sales climbed 33.5%, with international revenues surging more than 50%.PODD expanded gross and operating margins and guided 20%-22% CER revenue growth for 2026.Insulet Corporation (PODD) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.55, up 34.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 4.87%.GAAP EPS came in at $1.44, up ...

Insulet (NasdaqGS:PODD) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Company ParticipantsAshley McEvoy - President and CEOClare Trachtman - VP of Investor RelationsEric Benjamin - COOFlavia Pease - CFOJoanne Wuensch - Managing DirectorConference Call ParticipantsDanielle Antalffy - Managing Director and Senior Equity Research AnalystDavid Roman - Managing Director and Senior AnalystJeff Johnson - Managing Director and Senior Research AnalystLarry Biegelsen - Managing Director and Senior AnalystMichae ...

Insulet (NasdaqGS:PODD) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Company ParticipantsAshley McEvoy - President and CEOClare Trachtman - VP of Investor RelationsEric Benjamin - COOFlavia Pease - CFOJoanne Wuensch - Managing DirectorConference Call ParticipantsDanielle Antalffy - Managing Director and Senior Equity Research AnalystDavid Roman - Managing Director and Senior AnalystJeff Johnson - Managing Director and Senior Research AnalystLarry Biegelsen - Managing Director and Senior AnalystMichae ...

Insulet (NasdaqGS:PODD) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Speaker9Good morning, and welcome to the Insulet Corporation fourth quarter and full year 2025 earnings call. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Clare Trachtman, Vice President, Investor Relations.Speaker1Good morning, and welcome to our fourth quarter and full year 2025 earnings call. Joining me today are Ashley McEvoy, President and Chief Executive Offi ...

Financial Data and Key Metrics Changes - The company achieved over $700 million in quarterly revenue for the first time, reflecting a 28% year-over-year growth at constant currency rates and a 30% growth at reported rates [7][17] - Operating margins expanded by 90 basis points year-over-year to 17.1%, indicating improved profitability [7][22] - Gross margin reached 72.2%, reflecting a 290 basis point expansion year-over-year, driven by strong top-line growth and manufacturing productivity [20][21] Business Line Data and Key Metrics Changes - Total Omnipod revenue grew 29% year-over-year on a constant currency basis, with new customer starts increasing both year-over-year and sequentially in U.S. Type 1, U.S. Type 2, and international Type 1 markets [17][19] - U.S. Omnipod revenue grew 25.6%, driven by demand for Omnipod 5, particularly among Type 2 customers [19] - International Omnipod revenue grew 46.5% on a reported basis and 39.9% on a constant currency basis, crossing $200 million for the first time [20] Market Data and Key Metrics Changes - In the U.S. Type 1 market, the prescriber base expanded to over 27,000 healthcare professionals, contributing to sequential and year-over-year growth [8] - New customer starts in U.S. Type 2 more than doubled year-over-year, indicating strong momentum in this segment [8][9] - Internationally, revenue grew 40% year-over-year on a constant currency basis, driven by the rollout of Omnipod 5 [9][10] Company Strategy and Development Direction - The company aims to deepen its competitive advantage and drive penetration in both Type 1 and Type 2 markets through strategic investments in innovation and market development [11][12] - The focus on direct-to-consumer (DTC) campaigns has yielded record levels of qualified leads, enhancing brand awareness and adoption [13][21] - The company is committed to expanding its manufacturing capacity and integrating AI and cloud-based tools to streamline operations [14][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing broad-based and durable growth across its business model [14][29] - The outlook for the fourth quarter includes total Omnipod revenue growth of 27%-30% and total company growth of 25%-28% [24][25] - The company raised its full-year 2025 revenue growth guidance for total Omnipod to 29%-30% and total company growth to 28%-29% [26][27] Other Important Information - The company successfully eliminated all convertible debt from its capital structure, enhancing financial flexibility [23] - The new CFO emphasized the importance of providing balanced guidance that reflects both risks and opportunities [24][56] Q&A Session Summary Question: Insights on Omnipod 5's success amidst increasing competition - Management highlighted broad-based growth driven by strong science, a beloved brand, differentiated access, and a resilient supply chain [33][35] Question: Adoption of Type 2 indication and DTC advertising impact - Management noted significant growth in prescribers and new customer starts for Type 2, attributing this to strong science and DTC investments [38][40] Question: Strategy for maintaining momentum with a new leadership team - Management emphasized leveraging strong technology, investing in market development, and maintaining a strategic capital allocation strategy [44][46] Question: Guidance practices and outlook for 2026 - Management plans to provide a balanced view of expectations, acknowledging risks while highlighting growth opportunities [52][56] Question: Competitive positioning against new entrants in the patch pump market - Management focused on expanding the market and leveraging existing relationships with prescribers to maintain leadership [59][61] Question: International performance and volume dynamics - Management confirmed robust growth driven primarily by volume, with no significant impact from distributor stocking [66][70] Question: U.S. Omnipod growth drivers and sustainability - Management indicated ongoing education efforts and strong performance from both Type 1 and Type 2 markets as key growth drivers [73][78]

Core Insights - Insulet (PODD) has experienced a significant share price increase of 37.4% over the past year, outperforming the industry decline of 0.5% and the S&P 500's gain of 17.5% [1][8] - The company is enhancing its leadership in the diabetes market through the Omnipod 5, which is driving strong adoption and market growth [1][3] Company Overview - Insulet, based in Acton, MA, specializes in manufacturing and selling continuous insulin delivery systems for insulin-dependent diabetes [2] - The Omnipod platform offers a unique, tubeless insulin delivery system and is available in 25 countries [2] Growth Drivers - The share price rally is attributed to the strong momentum of Omnipod 5, the only FDA-cleared, fully disposable pod-based automated insulin delivery system [3] - Key product features such as on-body wearability and ease of use are contributing to rapid adoption [3] - Recent milestones include the U.S. launch of the Omnipod 5 App integrated with Dexcom G7 CGM system [3][4] Market Expansion - Omnipod DASH is gaining traction in the U.S. type 2 diabetes market, accounting for approximately 30% of new starts [4] - Insulet has received FDA clearance for type 2 label expansion for Omnipod 5, further enhancing its market position [4] - The company is expanding its market presence in Europe and has launched Omnipod Discover, a digital platform for personalized data management [5] Market Potential - The diabetes market remains underpenetrated, with only about 40% of the Type 1 diabetes population in the U.S. using insulin pump therapy [6] - Insulet is focusing on commercial expansion and market access, including salesforce growth and targeted pediatric center entry [9] Financial Estimates - The Zacks Consensus Estimate projects Insulet's earnings per share (EPS) to increase by 42.9% in 2025 and 24.3% in 2026, reaching $4.63 and $5.76 respectively [11] - Revenues are expected to grow by 26.4% in 2025 to $2.62 billion and by 18.1% in 2026 to $3.09 billion [11]

Core Insights - Insulet Corporation (PODD) has experienced significant share price growth of 77.2% over the past year, outperforming the industry growth of 4.6% and the S&P 500 Composite's increase of 14.3% [1][8] - The company is recognized for its strong fundamentals and growth opportunities, making it a solid investment option at present [1] Company Overview - Insulet develops and markets the Omnipod System, a continuous insulin delivery system designed for individuals with insulin-dependent diabetes, which includes the Omnipod and the next-generation Omnipod DASH [2] - The company reports revenues through three segments: U.S. Omnipod, International Omnipod, and Drug Delivery, with the latter involving partnerships with pharmaceutical companies for customized drug delivery [3] Growth Drivers - Insulet's share price growth is supported by strategic market expansion, including FDA clearance for the Omnipod 5's type 2 label expansion, which has broadened the addressable market to over 5.5 million U.S. patients [4][5] - The Omnipod 5 system has shown strong performance, with significant growth in new customer starts and revenue across all business segments in Q2 2025 [5][8] - The introduction of Omnipod Discover, a digital platform for personalized data management and patient engagement, further enhances the company's consumer-focused innovation strategy [6] Financial Performance - Insulet reported a second-quarter operating profit of $121.1 million, reflecting a 122.2% year-over-year increase, with operating margins expanding by 750 basis points [9] - The company ended Q2 2025 with cash and cash equivalents of $1.12 billion and current debt of $461 million, indicating strong financial stability [9] Market Challenges - Insulet faces potential vulnerabilities due to macroeconomic volatility, including geopolitical conflicts and supply chain disruptions, which may impact product costs [10] - The competitive landscape and regulatory conditions in the markets may limit the company's ability to implement price increases or other cost-driving strategies [11] Earnings Estimates - The Zacks Consensus Estimate for Insulet's 2025 EPS has increased by 6% to $4.59 in the past 30 days, with an earnings yield of 1.4%, outperforming the industry's -0.8% [12]

Financial Data and Key Metrics Changes - The company reported revenue of $649 million for the quarter, representing a 31% year-over-year growth, surpassing the $600 million mark for the first time [8][30] - Adjusted operating margin expanded to 17.8%, and adjusted EBITDA margin was 24.3% for the quarter [35][36] - The company raised its full-year revenue growth guidance to a range of 24% to 27% [40][44] Business Line Data and Key Metrics Changes - U.S. revenue grew by 28.7%, driven by strong demand for Omnipod five, with new customer starts increasing year-over-year and sequentially [32][29] - International revenue grew by 38.8%, primarily due to demand for Omnipod five and customer base growth [33][34] - Over 85% of U.S. new customer starts came from multiple daily injections (MDI), with over 30% being Type two patients [29][30] Market Data and Key Metrics Changes - The international business accounted for approximately 30% of total revenues, with significant growth in the UK, France, and Germany [22][34] - The company has expanded Omnipod five to 14 markets, driving strong adoption and positive price mix realization [53][72] - The U.S. market remains the largest customer base, with over 25,000 healthcare providers prescribing Omnipod five, reflecting a 20% increase from the previous year [12][12] Company Strategy and Development Direction - The company aims to enhance commercial capabilities, build brand power globally, drive operational and financial scale, and accelerate innovation [25][27] - Focus on expanding the Type two market while maintaining leadership in Type one, leveraging strong clinical evidence and market access [21][57] - Continued investment in manufacturing capabilities and automation to meet growing global demand [14][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's unique strengths and future growth potential, citing a large underpenetrated market and strong brand engagement [18][28] - The company is committed to driving at least 100 basis points of adjusted operating margin expansion annually [45] - Management highlighted the importance of integrating new technologies and maintaining strong relationships with healthcare providers to drive adoption [24][90] Other Important Information - The company ended the quarter with $1.1 billion in cash and $500 million available under its credit facility [36] - The company repurchased 93,000 shares for approximately $30 million under its share repurchase authorization [38] - A leadership update was announced, with Claire Trachman joining as the new Vice President of Investor Relations [48] Q&A Session Summary Question: Drivers of upside in U.S. and international markets - Management noted strong adoption in Type one and Type two markets, with significant growth in new customer starts and effective integration of clinical evidence [50][51] Question: Acceleration in Type two new starts - The company highlighted strong clinical evidence, market access, and ease of use as key drivers for the acceleration in Type two new starts [56][58] Question: Guidance framework and expectations - Management indicated that guidance reflects strong business fundamentals and momentum, with a focus on realistic targets [61][63] Question: International expansion strategy - The company is focused on deepening penetration in existing markets while exploring new markets in a financially disciplined manner [70][72] Question: Competitive conversions and MDI growth - Management confirmed that both MDI and competitive conversions have accelerated, driven by impactful innovation and strong market execution [105][108] Question: Go-to-market strategy for primary care vs. endocrinologists - The company is adapting its strategy to engage primary care physicians, leveraging the simplicity of its technology to drive adoption among Type two patients [110][112]